Abstract
Background Adverse reactions to warfarin may be serious and can lead to hospitalisation or death. Minimising the risk of adverse drug reactions through the intervention of community pharmacists is important for patients receiving warfarin, especially for elderly (≥ 65 years) patients living in rural areas. Objective To evaluate the impact of an intervention by community pharmacists on the risk of adverse drug reactions in elderly rural patients receiving warfarin. Setting: A community pharmacy in a rural area of Croatia. Method We conducted a prospective randomised trial. Eligible patients were recruited at the pharmacy and randomised into one of two groups. The participants were followed up every month for 6 months. Main outcome measure: The incidence and type of adverse drug reactions caused by warfarin and the time-to-event. Results In total, 140 patients were randomized and 131 patients completed the study; 65 patients were in the intervention group. The median age of patients was 73 years of age. The cumulative incidence of adverse drug reactions was significantly lower in the intervention group (6-months rate 29% vs. 85% for intervention and control, respectively; hazard ratio = 0.17, p < 0.001) than in the control group. Factors multivariately associated with the development of adverse drug reactions related to warfarin (p < 0.05) were the absence of pharmaceutical intervention, higher time in therapeutic range, change of warfarin dose, changes in dietary vitamin K intake, and marital status other than married. Conclusion Overall, the pharmacist’s intervention significantly prolonged the time to occurrence of adverse drug reactions and reduced their incidence.
Similar content being viewed by others
References
Patel TK, Patel PB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol. 2018;74:819–32.
Pirmohamed M, Scott AK, Green C, Farrar K, Park BK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–9.
Kim MM, Metlay J, Cohen A, et al. Hospitalization costs associated with warfarin-related bleeding events among older community-dwelling adults. Pharmacoepidemiol Drug Saf. 2010;19(7):731–6.
Mearns ES, White CM, Kohn CG, Hawthorne J, Song J-S, Meng J, et al. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J. 2014;12:14.
Hanlon JT, Pieper CF, Hajjar ER, Sloane RJ, Lindblad CI, Ruby CM, et al. Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay. J Gerontol A Biol Sci Med Sci. 2006;61(5):511–5.
Manji I, Pastakia SD, Do AN, Ouma MN, Schellhase E, Karwa R, et al. Performance outcomes of a pharmacist-managed anticoagulation clinic in the rural, resource-constrained setting of Eldoret, Kenya. J Thromb Haemost. 2011;9:2215–20.
Young S, Bishop L, Twells L, Dillon C, Hawboldt J, O’Shea P, et al. Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic. BMC Fam Pract. 2011;12:88.
Falamić S, Lucijanić M, Hadžiabdić MO, Marušić S, Bačić Vrca V. Pharmacist’s interventions improve time in therapeutic range of elderly rural patients on warfarin therapy: a randomized trial. Int J Clin Pharm. 2018;40(5):1078–85.
Singh S, Bajorek B. Defining, “elderly” in clinical practice guidelines for pharmacotherapy. Pharm Pract (Granada). 2014;12(4):489.
Brezzi M, Dijkstra L, Ruiz V. OECD extended regional typology: the economic performance of remote rural regions. OECD Regional Development Working Papers, 2011/06, OECD Publishing. http://dx.doi.org/10.1787/5kg6z83tw7f4-en Accessed 15 May 2019.
Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029–37.
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72.
Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100.
Franco V, Polanczyk CA, Clausell N. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med. 2004;116(10):651–6.
Franceschi M, Scarcelli C, Niro V, Seripa D, Pazienza AM, Pepe G, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a Geriatric Unit: a prospective study of 1756 patients. Drug Saf. 2008;31:545–56.
Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123:2736–47.
Lucijanic M, Skelin M, Lucijanic T. Survival analysis, more than meets the eye. Biochem Med (Zagreb). 2017;27(1):14–8.
Lucijanić M. Survival analysis in clinical practice: analyze your own data using an Excel workbook. Croat Med J. 2016;57(1):77–9.
Saokaew S, Sapoo U, Nathisuwan S, Chaiyakunapruk N, Permsuwan U. Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand. Int J Clin Pharm. 2012;34(1):105–12.
Daniels PR, Manning DM, Moriarty JP, Bingener-Casey J, Ou NN, O’Meara JG, et al. Improving inpatient warfarin therapy safety using a pharmacist-managed protocol. BMJ Open Qual. 2018;7:e000290.
Lee T, Davis E, Kielly J. Clinical impact of a pharmacist-led inpatient anticoagulation service: a review of the literature. Integr Pharm Res Pract. 2016;5:53–63.
Airee A, Guirguis AB, Mohammad RA. Clinical outcomes and pharmacists’ acceptance of a community hospital’s anticoagulation management service utilizing decentralized clinical staff pharmacists. Ann Pharmacother. 2009;43(4):621–8.
Damaske DL, Baird RW. Development and implementation of a pharmacist-managed inpatient warfarin protocol. Proc (Bayl Univ Med Cent). 2005;18(4):397–400.
Tschol N, Lai DK, Tilley JA, Wong H, Brown GR. Comparison of physician- and pharmacist-managed warfarin sodium treatment in open heart surgery patients. Can J Cardiol. 2003;19(12):1413–7.
Chilipko AA, Norwood DK. Evaluating warfarin management by pharmacists in a community teaching hospital. Consult Pharm. 2014;29(2):95–103.
Schillig J, Kaatz S, Hudson M, Krol GD, Szandzik EG, Kalus JS. Clinical and safety impact of an inpatient pharmacist-directed anticoagulation service. J Hosp Med. 2011;6(6):322–8.
Burns N. Evaluation of warfarin dosing by pharmacists for elderly medical in-patients. Pharm World Sci. 2004;26(4):232–7.
Rivey MP, Wood RD, Allington DR, Stratton TP, Erickson CC, Stenson TA. Pharmacy-managed protocol for warfarin use in orthopedic surgery patients. Am J Health Syst Pharm. 1995;52(12):1310–6.
Manzoor BS, Cheng WH, Lee JC, Uppuluri EM, Nutescu EA. Quality of pharmacist-managed anticoagulation therapy in long-term ambulatory settings: a systematic review. Ann Pharmacother. 2017;51:1122–37.
Harper P, Mcmichael I, Griffiths D, Harper J, Hill C. The community pharmacy-based anticoagulation management service achieves a consistently high standard of anticoagulant care. N Z Med J. 2015;128(1422):31–41.
Stafford L, Peterson GM, Bereznicki LR, et al. Clinical outcomes of a collaborative, home-based postdischarge warfarin management service. Ann Pharmacother. 2011;45(3):325–34.
Knežević A, Nadinić M, Užović Frakin I, Trkulja V. Poor warfarin anticoagulation in long-term thromboprophylaxis: a survey in a southern Croatian county. Croat Med J. 2019;60(1):2–11.
Costa GLDB, Lamego RM, Colosimo EA, Valacio RA, Moreira MDCV. Identifying potential predictors of high-quality oral anticoagulation assessed by time in therapeutic international normalized ratio range: a prospective, long-term, single-center, observational study. Clin Ther. 2012;34(7):1511–20.
Vestergaard AS, Skjøth F, Larsen TB, Ehlers LH. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: a systematic review and meta-regression analysis. PLoS ONE. 2017;12(11):e0188482.
Marusic S, Bacic-Vrca V, Obreli Neto PR, Franic M, Erdeljic V, Gojo-Tomic N. Actual drug-drug interactions in elderly patients discharged from internal medicine clinic: a prospective observational study. Eur J Clin Pharmacol. 2013;69:1717–24.
Urbonas G, Valius L, Šakalytė G, Petniūnas K, Petniūnienė I. The quality of anticoagulation therapy among warfarin-treated patients with atrial fibrillation in a primary health care setting. Medicina (Kaunas). 2019;55(1):1–15.
Zhang J, Liu M, Chen Q, Wu J, Cao H. Outcomes of an online pharmacist-managed anticoagulation clinic for individuals on warfarin therapy living in rural communities. Thromb Res. 2017;157:136–8.
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.
Acknowledgements
This study is a part of the Ph.D. thesis of the first author. The authors would like to acknowledge all the general practitioners responsible for the study participants for the provision of the required data.
Funding
This study was self-funded.
Conflicts of interest
The authors declare that they have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Falamić, S., Lucijanić, M., Ortner-Hadžiabdić, M. et al. Pharmacists’ influence on adverse reactions to warfarin: a randomised controlled trial in elderly rural patients. Int J Clin Pharm 41, 1166–1173 (2019). https://doi.org/10.1007/s11096-019-00894-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11096-019-00894-4